Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.97M P/E - EPS this Y 46.00% Ern Qtrly Grth -
Income -40.16M Forward P/E -0.74 EPS next Y 7.80% 50D Avg Chg -34.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 0.58 EPS next 5Y - 52W High Chg -52.00%
Recommedations 1.70 Quick Ratio 2.51 Shares Outstanding 21.41M 52W Low Chg 49.00%
Insider Own 25.00% ROA -68.72% Shares Float 17.61M Beta 0.81
Inst Own 40.77% ROE -136.38% Shares Shorted/Prior 799.87K/442.40K Price 0.94
Gross Margin - Profit Margin - Avg. Volume 87,761 Target Price 9.00
Oper. Margin - Earnings Date May 9 Volume 163,146 Change -7.84%
About Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Vincerx Pharma, Inc. News
04/09/24 Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
04/09/24 Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
04/08/24 Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
04/01/24 Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/29/24 Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look
03/29/24 Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
03/14/24 12 Most Profitable Biotech Stocks To Invest In
03/05/24 Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/05/24 Vincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past week
01/07/24 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
12/19/23 15 Best Falling Stocks To Buy Now
12/10/23 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
11/14/23 Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/02/23 Vincerx Pharma To Present Three Posters at ASH 2023 in December
10/13/23 New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network
10/06/23 New to The Street Announces TV Corporate Appearances, Broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ET
09/19/23 Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
09/14/23 Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
08/22/23 Vincerx Pharma Announces FDA Clearance of IND for VIP943
08/14/23 10 Oversold Penny Stocks To Buy
VINC Chatroom

User Image CON_or_McGregor Posted - 1 hour ago

$VINC I'm thinking a BO is imminent. I would imagine 100 mil is a good price 🤑🤗🥲

User Image new_jack Posted - 6 hours ago

$VINC hope you’re buying this up. don’t regret it when we’re back in dollar land.

User Image Lotsofdollars Posted - 7 hours ago

$VINC hold nicely but I am sure it will go up next two days

User Image GPS_OS_21_vs_SOC_5 Posted - 8 hours ago

$VINC P1 -- Long road, and early Results Showed No Safety, and No Efficacy - a long costly road and there are many, many ADC competitors way Ahead in the Game. Don't forget the whole market knows Hamdy, pitched early VIP150/152 Data as Efficacious and Safe -- it Wasn't and isn't, that's why they defunded it. A massive Offering is coming, then R/S - mark this post.

User Image stevelue Posted - 8 hours ago

$VINC started an Uptrend beginning 4/15 per 5 day chart...Good Technical

User Image GreenTsunami Posted - 9 hours ago

$VINC come on low volume day, buy up and get the momentum going. Penny flipping won't earn investors money. This is worth more than $5 a share during the big drop. Earnings and announcements coming in May and then more data in June. I misjudged the spike but this company is moving forward and quickly advancing. Money comes and goes, but the results and science show we are holding a winning pipeline. The more results we get will only further validate this point.

User Image thielindo Posted - 11 hours ago

$VINC got my average down alot now let's pray for better days

User Image Businesspro Posted - 11 hours ago

$VINC Remember guys this already fell 78% few weeks ago… IMO time for a bounce

User Image stevelue Posted - 11 hours ago

$VINC close that big GAP upwards!

User Image precise Posted - 12 hours ago

Nearly all ADCs target the same stuff, it’s oversaturated. $VINC is highly differentiated and has a bunch of novel products. You wonder if BP may have interest once concepts are proven.

User Image Businesspro Posted - 12 hours ago

$VINC IMO chart setting up nicely now 👍

User Image phatmatt511 Posted - 12 hours ago

$VINC

User Image ViractaTrader77 Posted - 13 hours ago

$STRO Cantor Fitzgerald sees another strong year ahead for oncology M&A, with companies focused on antibody drug conjugates, radiopharmaceuticals and T-cell engagers expected to attract increased attention from major drugmakers looking to replenish pipelines. Impending patent cliffs will be a big motivator for deals. According to Cantor, around $182B in revenue is at risk over the next four years due to patent expirations, with oncology products accounting for 42% of that number. $VINC

User Image Rollercoaster22 Posted - 21 hours ago

$VINC

User Image Highbank Posted - 23 hours ago

$VINC Holy cow, what happened here?😳

User Image telomerase Posted - 1 day ago

$VINC Vincerx IR assures me that getting our capital is their highest priority. I had hoped that designing SMDCs was their highest priority, but at least their IR actually does send out vague responses when prompted. And VINC insiders do have serious stakes in the company. https://www.secform4.com/insider-holders/1796129.html ---------------------------------------- Dear Mr. Walker, Thank you for reaching out and for your continued support. I want to assure you that bringing in the capital we need to ensure the continued success of our programs and maximize shareholder value is our highest priority. I should also mention that our founders and management are major shareholders of this company, so our interests are very much aligned here. As soon as we have information to share, we will do so, as we’ve always done, via press releases and/or public filings. Thank you, Gabriela

User Image ViractaTrader77 Posted - 1 day ago

VIP 236 will have robust data like Prolynx and SN bioscience. Just matter of higher dosing.. same thing sn-38 https://prolynxinc.com/PLX038.html $VINC

User Image Telgar Posted - 1 day ago

$VINC A nice constructive turnaround with the volume to support the change of sentiment.

User Image canecoleman Posted - 1 day ago

@S_Franconi @telomerase Once again, you can thank @telomerase for the incessant bullshit spamming of $SLS that led to our sharing of very bearish sentiments for $VINC on your board.

User Image canecoleman Posted - 1 day ago

@S_Franconi @telomerase actually, it was @telomerase who harmed all of the $VINC supporters lmao

User Image Dtwod7474 Posted - 1 day ago

$VINC I think the consolidation period is short lived. If you were waiting to average down on the upward this might be your last chance.

User Image phatmatt511 Posted - 1 day ago

$VINC

User Image Str8BALTShtr Posted - 1 day ago

$VINC Okay, so has it made the turn? Er, is it just a lil gas after a big meal?

User Image GPS_OS_21_vs_SOC_5 Posted - 1 day ago

$VINC

User Image ViractaTrader77 Posted - 1 day ago

$VINC This puts a value imo on our warhead cell trapper technology. Same kind of effect. https://www.buffalo.edu/ubnow/stories/2024/04/balthasar-abceutics-merck.html

User Image precise Posted - 1 day ago

$VINC Viracta is back in full capacity

User Image ViractaTrader77 Posted - 1 day ago

$VINC $5 stock. An-38 data early. Look at peers data at higher doses. https://www.prnewswire.com/news-releases/sn-bioscience-announces-phase-1-study-results-of-snb-101-sn-38-nanoparticle-anti-cancer-drug-at-esmo-301969813.html

User Image ViractaTrader77 Posted - 1 day ago

$VINC Worth at least $5.00 per share. Data was fine it’s just beginning. SN Bioscience data was stellar on their SN-38 expect hot data the next go round. All their stellar data came multiples hire power wise. At 50 mg Orr was off the hook. https://www.prnewswire.com/news-releases/sn-bioscience-announces-phase-1-study-results-of-snb-101-sn-38-nanoparticle-anti-cancer-drug-at-esmo-301969813.html

User Image Rollercoaster22 Posted - 1 day ago

$VINC The only way is up!

User Image stevelue Posted - 1 day ago

$VINC Volume coming in here now!

Analyst Ratings
Cantor Fitzgerald Overweight Apr 9, 24
Cantor Fitzgerald Overweight Apr 1, 24
Cantor Fitzgerald Overweight Sep 7, 23
Chardan Capital Buy Nov 17, 22
SVB Leerink Outperform Aug 12, 22
Cantor Fitzgerald Overweight Jun 8, 22
B. Riley Securities Buy Jun 7, 22
Chardan Capital Buy Jun 7, 22
SVB Leerink Outperform Jun 7, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hamdy Ahmed MD See Remarks See Remarks Aug 09 Buy 0.95 22,300 21,185 96,060 08/10/23
THOMAS TOM C See Remarks See Remarks Aug 10 Buy 0.95 5,000 4,750 219,935 08/10/23
Izumi Raquel E. See Remarks See Remarks Aug 09 Buy 0.92 16,476 15,158 85,214 08/10/23
Izumi Raquel E. See Remarks See Remarks Dec 14 Buy 0.8848 28,738 25,427 68,738 12/14/22
Hamdy Ahmed MD Chief Executive Offi.. Chief Executive Officer Dec 14 Buy 0.8656 35,280 30,538 73,760 12/14/22
THOMAS TOM C See Remarks See Remarks Dec 14 Buy 0.83 7,000 5,810 10,000 12/14/22
Hamdy Ahmed MD Chief Executive Offi.. Chief Executive Officer Jun 23 Buy 1.4106 24,200 34,137 38,480 06/27/22
Bushnell Laura I. Director Director Jun 09 Buy 1.9083 15,000 28,624 19,202 06/13/22